On Tuesday, Shares of Biogen Inc (NASDAQ:BIIB), gained 1.95% to $403.94.
Biogen is one of the world’s oldest biotechnology companies and was founded in 1978 in Geneva. The company researches, develops and markets innovative therapies. Biogen employs more than 7,500 people in 30 countries. In the Greater Zurich Area, Biogen has been present for more than 10 years when, in 2003, the third largest biotech company was created by the merger of Biogen and Idec Pharmaceuticals to become Biogen Idec. Since 2004, the head office of Biogen International has been located in the canton of Zug. In Switzerland, the company presently employs about 300 people.
Following recent signing of the preliminary contract between the canton of Solothurn and Biogen, Natascha Schill, CEO of Biogen Switzerland, said: “Thanks to the excellent support of the canton of Solothurn, the Commune Luterbach and the federal administration, we have the opportunity to build one of the most advanced production facilities in the world. The canton of Solothurn provides business-friendly environment, reliable infrastructure, and access to well-trained labor force.”
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally.
Shares of DS Healthcare Group Inc (NASDAQ:DSKX), inclined 8.19% to $2.51, during its last trading session.
DS Healthcare Group, joined the Russell Microcap Index at the conclusion of the Russell indexes annual reconstitution on June 26.
Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
DS Healthcare Group, Inc., doing business as DS Laboratories, develops and markets hair care, skin care, and personal care products in North America and internationally.
Finally, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), ended its last trade with 1.19% gain, and closed at $123.48.
Vertex Pharmaceuticals Incorporated, declared that the companies will collaborate to develop investigational epithelial sodium channel (ENaC) inhibitors for the potential treatment of cystic fibrosis (CF) and other pulmonary diseases. Under the agreement, Vertex gains worldwide development and commercial rights to Parion’s investigational ENaC inhibitors, counting P-1037 and P-1055, for CF and other pulmonary diseases. P-1037 is presently being evaluated in an exploratory Phase 2a study in people with CF, regardless of genotype, and Vertex and Parion plan to start an additional Phase 2a study that adds P-1037 to treatment with the investigational combination of lumacaftor and ivacaftor for people with CF who have two copies of the F508del mutation. Parion will receive an $80 million up-front payment from Vertex with the potential to receive additional development and regulatory milestone payments and tiered royalties related to P-1037 and P-1055 in CF and other pulmonary diseases.
“This partnership with Parion complements our ongoing work in CF and supports our two key aims in this disease – to enhance the number of people eligible for new CF medicines and to enhance the benefit of treatment,” said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical Officer at Vertex. “The aim of these planned studies of P-1037 is to determine whether ENaC inhibition can improve lung function in people with CF, counting those with mutations unlikely to respond to treatment with the investigational combination of lumacaftor and ivacaftor. Beyond CF, this agreement assists to diversify our pipeline by providing opportunities to evaluate P-1037 as part of Phase 2a studies in multiple other diseases that impact the lungs.”
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
